According to the European guideline on the medical management of pediatric CD, ustekinumab can be considered in patients who fail to achieve or maintain clinical remission on adequately dosed anti-TNF agents (infliximab or adalimumab) in combination with immunomodulator use (van Rheenen et al., 2020). This evidence concerns the gene TNF and Cowden disease.